Loading…
DiaMedica Therapeutics Inc. is projected to rise to $6.40 by 2027, a +5% move from its current price of $6.10. DMAC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.93 | $6.10 | $6.27 | -0.01% |
| May 30 | $5.86 | $6.10 | $6.34 | -0.02% |
| May 31 | $5.81 | $6.10 | $6.40 | -0.03% |
| Jun 1 | $5.77 | $6.10 | $6.45 | -0.04% |
| Jun 2 | $5.73 | $6.10 | $6.49 | -0.05% |
| Jun 3 | $5.69 | $6.10 | $6.53 | -0.06% |
| Jun 4 | $5.66 | $6.10 | $6.56 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.66 | $6.10 | $6.56 | -0.07% |
| Week 2 | $5.49 | $6.09 | $6.76 | -0.15% |
| Week 3 | $5.36 | $6.09 | $6.92 | -0.22% |
| Week 4 | $5.25 | $6.08 | $7.05 | -0.29% |
| Week 5 | $5.15 | $6.08 | $7.17 | -0.36% |
| Week 6 | $5.07 | $6.07 | $7.28 | -0.44% |
| Week 7 | $4.99 | $6.07 | $7.38 | -0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
DiaMedica Therapeutics Inc. is a healthcare company that operates as a clinical stage biopharmaceutical firm focused on ischemic diseases. Its lead candidate, DM199, is a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein and is in Phase 2/3 trials for acute ischemic stroke, as well as in Phase 2 trials to treat preeclampsia, cardio renal disease, and fetal growth restriction.
The company also develops DM300, a recombinant human ulinastatin in the preclinical stage for inflammatory diseases such as acute pancreatitis. DiaMedica Therapeutics Inc. was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. It was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc. (DMAC) currently trades in the healthcare sector with a price of $5.91 and a market capitalization of $318.45M. The stock holds a rank of 3464.
Near-term forecasts show price activity around the current level, while the longer-horizon path points to meaningful upside. The 2026 forecast lists an average price of $5.91 with a min of $5.57 and a max of $7.47, and an ROI of 0, reflecting a neutral near-term view. By 2030 the average price rises to $8.13 with a min of $6.10 and a max of $11.65, delivering an estimated ROI of 37.5 and a bullish tilt.
Looking further out, the forecast envisions continued upside through 2031–2035 and into 2040 and 2050, with 2040 averaging $17.29 (ROI 192.5) and 2050 averaging $32.51 (ROI 450.1). The max prices for these years rise to $28.47 (2040) and $58.26 (2050). These projections reflect a longer-term bullish trajectory but remain estimates, not guarantees.
A major floor 19.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.7% below — buyers have tended to step in here.
The nearest ceiling, 12.3% above — a clean break opens room to run.
A major ceiling 43.6% above — clearing it would confirm fresh momentum.
Key DMAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.96 | Buy | $6.04 | Buy |
| MA 10 | $5.98 | Buy | $6.03 | Buy |
| MA 20 | $6.12 | Sell | $6.12 | Sell |
| MA 50 | $6.41 | Sell | $6.49 | Sell |
| MA 100 | $7.28 | Sell | $6.84 | Sell |
| MA 200 | $7.17 | Sell | $6.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.78 | Neutral |
| Stoch RSI (14) | 75.96 | Neutral |
| CCI (20) | -5.46 | Neutral |
| Williams %R (14) | -44.79 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.48 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 55.21 | Neutral |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 47.49 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 6.12 | Sell |
| ADX (14) | 15.85 | Neutral |
| ATR (14) | 0.18 | Info |
Near term, the sentiment is Bearish. The RSI(14) is 40, and the stock trades below the SMA50 of $6.45 and SMA200 of $7.15, suggesting limited bullish momentum against the longer-term trend.
The near-term support is at $5.57, with resistance at $6.85. The 30-day range spans from $5.01 to $6.97, highlighting tight price action around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.57 | $6.10 | $7.77 | 0% | Neutral | |
| $5.07 | $6.40 | $8.58 | +5% | Neutral | |
| $5.26 | $6.83 | $9.49 | +12% | Neutral | |
| $5.48 | $7.28 | $10.41 | +19% | Neutral | |
| $6.22 | $8.45 | $12.38 | +39% | Bullish | |
| $7.04 | $9.74 | $14.58 | +60% | Bullish | |
| $7.84 | $11.04 | $16.84 | +81% | Bullish | |
| $7.95 | $11.37 | $17.65 | +86% | Bullish | |
| $7.55 | $10.98 | $17.31 | +80% | Bullish | |
| $8.08 | $11.93 | $19.09 | +96% | Bullish | |
| $11.44 | $18.09 | $30.81 | +197% | Bullish | |
| $19.40 | $34.56 | $64.45 | +467% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.57 | $6.10 | $7.16 | +0.00% |
| June 2026 | $5.09 | $5.98 | $7.19 | -2.02% |
| July 2026 | $5.10 | $6.04 | $7.37 | +1.10% |
| August 2026 | $5.22 | $6.23 | $7.68 | +3.12% |
| September 2026 | $5.13 | $6.15 | $7.65 | -1.23% |
| October 2026 | $4.97 | $5.99 | $7.51 | -2.64% |
| November 2026 | $5.01 | $6.07 | $7.66 | +1.30% |
| December 2026 | $5.03 | $6.12 | $7.77 | +0.80% |
Click any year to see its month-by-month DMAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DMAC to range from $5.57 to $7.77 through 2026. The $6.10 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DMAC price prediction for 2027 points to an average of $6.40 (low $5.07, high $8.58) — a potential gain of +5% on today's $6.10. A consolidation phase looks the most probable path here.
In 2028, DMAC is projected to trade between $5.26 and $9.49, averaging $6.83 — a potential gain of +12% from today's $6.10. That is up +7% on the projected 2027 average. Price action looks broadly range-bound.
DiaMedica Therapeutics Inc.'s 2029 outlook centres on $7.28, within a $5.48 to $10.41 range. That is up +7% on the projected 2028 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, DMAC could reach as high as $12.38, with a base case around $8.45 and support toward $6.22 — roughly +39% from $6.10. Momentum favours further upside here.
Expect DMAC to range from $7.04 to $14.58 through 2031. The $9.74 average target implies a +60% move from current prices. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DMAC price prediction for 2032 points to an average of $11.04 (low $7.84, high $16.84) — a potential gain of +81% on today's $6.10. Momentum favours further upside here.
In 2033, DMAC is projected to trade between $7.95 and $17.65, averaging $11.37 — a potential gain of +86% from today's $6.10. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
DiaMedica Therapeutics Inc.'s 2034 outlook centres on $10.98, within a $7.55 to $17.31 range. That is -3% versus the projected 2033 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2035, DMAC could reach as high as $19.09, with a base case around $11.93 and support toward $8.08 — roughly +96% from $6.10. Buyers look set to stay in control over this stretch.
Expect DMAC to range from $11.44 to $30.81 through 2040. The $18.09 average target implies a +197% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The DMAC price prediction for 2050 points to an average of $34.56 (low $19.40, high $64.45) — a potential gain of +467% on today's $6.10. Buyers look set to stay in control over this stretch.
Investing $1,000 in DMAC today (≈ 163.934426 DMAC) could be worth
$5,665.02
+$4,665.02 (+467%) by 2050 · US Dollar
Based on the average projected DMAC price of $34.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMACwould be worth at today's price.
$1,000 invested in DMAC on May 27, 2025 (≈ 240.96385 DMAC) would be worth
$1,469.88
+$469.88 (+47.0%) today · 1.47× · US Dollar
Based on a DMAC entry price of $4.15 vs. today's $6.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.72 | $1,066.43 | +6.6% |
| 1 month ago | $6.32 | $965.19 | -3.5% |
| 3 months ago | $8.23 | $741.19 | -25.9% |
| 6 months ago | $8.63 | $706.84 | -29.3% |
| 1 year ago | $4.15 | $1,469.88 | +47.0% |
| All time (5.0y) ago | $7.53 | $810.09 | -19.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMAC forecast.
Our base-case forecast reaches $12.00 around 2040.
Implied market cap at $12.00: $646.6M
The multi-year forecast shows a bullish trajectory beginning in 2030, with the 2030 average price of $8.13 and a 37.5 ROI, supported by a bullish sentiment for 2030 and beyond. The forecast continues to move higher in subsequent years, with 2040 averaging $17.29 and a 192.5 ROI, and 2050 averaging $32.51 with a 450.1 ROI. The 2030–2050 path implies substantial upside from the current level if the projections materialize.
From a longer-horizon perspective, the model envisions continued upside through 2031–2035 and beyond, with higher average prices and strong ROI figures (2031: 59, 2032: 77.5, 2033: 83.5, 2034: 80, 2035: 93.8; 2040: 192.5; 2050: 450.1). These are estimates and not guarantees, and actual results will depend on market conditions and clinical progress.
Overall, the long-term view suggests meaningful upside potential, while near-term price levels remain around the current price. Investors should consider the uncertainty inherent in speculative forecasts and the health-care development timeline when assessing DMAC.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $6.10, an average of $8.13, and a max of $11.65, with a ROI of 37.5 and a bullish sentiment.
Near-term expectations (2026) show an average price of $5.91 with a max of $7.47 and a 0 ROI, indicating neutral sentiment. The forecast turns increasingly bullish from 2030 onward, with higher average prices and positive ROIs through 2050.
The 2050 forecast lists a max of $58.26, with an average of $32.51 and a min of $19.30, and a ROI of 450.1, indicating bullish long-term potential.
The current price is $5.91 and the market capitalization is $318.45M.
Bearish sentiment with RSI(14) at 40. The 50-day SMA is $6.45 and the 200-day SMA is $7.15. Near-term support sits at $5.57 and resistance at $6.85. The 30-day range is $5.01 to $6.97.
DiaMedica Therapeutics Inc. Community Discussion
0Share your DiaMedica Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.